dc.contributor.author | Wilson, JM | |
dc.contributor.author | Parker, C | |
dc.date.accessioned | 2017-08-14T10:14:42Z | |
dc.date.issued | 2016-09 | |
dc.identifier.citation | Expert review of anticancer therapy, 2016, 16 (9), pp. 911 - 918 | |
dc.identifier.issn | 1473-7140 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/769 | |
dc.identifier.eissn | 1744-8328 | |
dc.identifier.doi | 10.1080/14737140.2016.1222273 | |
dc.description.abstract | Introduction A number of drugs have been shown to extend life expectancy in castration-resistant prostate cancer (CRPC). Skeletal related events (SREs) secondary to bone metastases cause significant morbidity for men with CRPC. The α-emitting radiopharmaceutical radium-223 dichloride has been shown to improve overall survival, time to symptomatic skeletal events (SSEs) and quality of life in CRPC.Areas covered The development of radium-223 from pre-clinical studies to the evidence of efficacy and safety from a phase 3 trial is discussed as well as its pharmacokinetics and metabolism. The integration of radium-223 into routine care for patients with advanced prostate cancer is included including a comparison with other agents in this setting. Expert commentary: The risk/benefit ratio for radium-223 is very similar to that of other agents used in the CRPC setting and is a treatment option for men unsuitable for cytotoxic chemotherapy because of comorbidities. The ALSYMPCA trial demonstrated an improvement in SSEs with radium-223. This is a clinically relevant end-point as not all radiologically-detected SREs are apparent to patients. The correct sequencing of the life-prolonging treatments available to men with CRPC is subject to debate. Radium-223 therapy should be considered before the development of visceral metastases. Drug-combination studies are underway. | |
dc.format | Print-Electronic | |
dc.format.extent | 911 - 918 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Animals | |
dc.subject | Humans | |
dc.subject | Bone Neoplasms | |
dc.subject | Radium | |
dc.subject | Radioisotopes | |
dc.subject | Antineoplastic Agents | |
dc.subject | Treatment Outcome | |
dc.subject | Survival Rate | |
dc.subject | Quality of Life | |
dc.subject | Male | |
dc.subject | Prostatic Neoplasms, Castration-Resistant | |
dc.title | The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-08-05 | |
rioxxterms.versionofrecord | 10.1080/14737140.2016.1222273 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2016-09 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Expert review of anticancer therapy | |
pubs.issue | 9 | |
pubs.notes | 12 months | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 16 | |
pubs.embargo.terms | 12 months | |
dc.contributor.icrauthor | Parker, Chris | |